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In this presentation, I will include a retrospective, breaking things down into arbitrary 
timeframes. I am defining the past as from the 950s through 99, the present from 
993 to 03, and the future from today onward (Figure ).
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Figure . Past, present and future.
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Past
Not long ago, DNA was identified as heritable material, and last year—0—we cel-
ebrated the 40th anniversary of the creation of the first recombinant-DNA organism, 
a bacterium (Figure ). The scientific community came together in the mid 970s, and 
as a group said:
Let’s take a break. Let’s look at the issue of safety. Let’s make sure that this new 
technology can be used safely.
They called on the National Institutes of Health to develop guidelines for the safe use of 
recombinant-DNA organisms in contained facilities; the guidelines were promulgated in 
976. The first commercial product from a recombinant organism was human insulin, 
marketed in 980. And, in 983, a recombinant plant was first described in the litera-
ture. I remember hearing about this as a beginning plant pathologist, and thinking that 
it would be a great tool for breeders as it touched upon the bedrock principle of using 
the best possible genetic basis to obtain resistance to pathogens.
The term “modern biotechnology” typically includes recombinant-DNA organisms 
(Figure ). In the United States and other countries, cell-fusion refers to combination 
of distantly related organisms; however, relatively little work has been done in this area. 
The note at the foot of Figure  is a reminder of the varied terminology that is used. Even 
the federal agencies use different terms, therefore one system cannot be laid on top of 
another, nationally or internationally. Internationally, “living modified organism” (LMO) 
is sometimes used, e.g. within the Cartagena Protocol. Everyone is familiar with GMO 
and “transgenic” is commonly used, whereas GEO seems almost archaic
Figure . Techniques of modern biology.
In my work for a regulatory agency, not only has my background in science been of 
utility, but so have my high-school civics classes. The combination has been essential in 
understanding the legal context within which the system operates. A necessary part of this 
is technical practicality; regulations must be enforceable. Of course, safety is a fundamental 
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consideration and public policy has a role. Some countries enact public policy aimed at 
promoting innovation or at tying their regulatory approach into a national system that 
assists development of the agricultural or the science and technology sector. And in recent 
years, international obligations have come into play increasingly.
The Coordinated Framework for Regulation of Biotechnology—proposed in 984 by 
the White House Office of Science and Technology Policy and finalized in 986—spells 
out the basic federal policy for regulating the development and introduction of products 
derived from biotechnology (Figure 3). This regulatory policy framework was developed 
to ensure safety of the public and to ensure the continuing development of the fledgling 
biotechnology industry without overly burdensome regulation. It applies as much today 
as it did in 986: in essence, the employment of these techniques does not, in and of 
itself, raise safety concerns. Also, federal laws, already enacted, cover any safety issues, 
and, if further regulation is needed, it should be based on the best available scientific 
information. Furthermore, applications for deregulation should be dealt with on a case-
by-case basis.
Figure 3. Coordinated Framework (986):
Federal role in the safe use of biotechnology.
APHIS regulation of GE organisms is pursuant to the Plant Quarantine Act (PQA) of 
9 and the Federal Plant Pest Act (FPPA) of 957. The original acts, which had nothing 
to do with genetically engineered organisms, were set up so that the federal government 
would have the ability to prevent plant pests—insects and pathogenic organisms—from 
coming into the country and moving interstate. These statutes were rolled together, along 
with the Noxious Weed Act, into the Plant Protection Act of 000. After vigorous de-
bate—should the USDA operate under federal regulations or operate under an advisory 
system akin to the National Institutes of Health Guidelines—it was decided to go with 
a legally binding system under regulations, put in place in 987.
Every regulation basically comes down to two parts: the item regulated and the activities 
of that item, which, under APHIS regulations (7CFR Part 340) is termed a “regulated 
article,” which has two parts to the trigger (Figure 4). The plant has been modified or 
produced using recombinant-DNA technology to modify the organism; and there has to 
be a possibility that the genetically engineered plant has a pest risk associated with it. In 
other words, if a recombinant DNA technique has been employed to modify an organism, 
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Figure 4. What does APHIS-BRS regulate?
and the donor organism, the recipient organism or the vector agent is a plant pest, then 
the resulting genetically engineered organism is called a “regulated article.” 
Over the years, people contacted us: “I’ve read the regulation and still don’t understand 
whether I have a regulated article.” A few years back, APHIS set up a website (Figure 4) 
that gives instructions on how to put together a letter of enquiry regarding a proposed 
or actual organism. No risk assessment involved. The feedback from APHIS is in terms 
of, “Yes, that meets the definition of a regulated article,” or “No, it does not meet the 
definition of a regulated article.” Fourteen such letters and APHIS’s responses are posted 
on the website. This has been an eye-opener for some who thought that if genetic en-
gineering techniques are involved, the item automatically falls under the regulations, 
which is not the case.
Figure 5 shows the activities that require authorization: importation to the United 
States; movement from state to state (not intrastate movement); and/or release into the 
environment. One of two authorization mechanisms may be applicable: the original 
permitting procedure that has been part of the regulation since 987; the notification 
procedure which was introduced in 993 to provide a more streamlined approach. Both 
procedures set out how the regulated article is to be authorized for importation, interstate 
movement and release into the environment. 
Present
Twenty years, 993–03, is a generous time span for “the present” (Figure ). In 993, 
we added something that the original regulations had no provision for: the commer-
cialization of genetically engineered plants. A farmer could not be expected to obtain 
permits and notifications every time (s)he moved genetically engineered seed or planted 
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Figure 5. Introduction of regulated articles.
a genetically engineered crop. We established a procedure whereby someone can petition 
us, in writing, for review to request that their genetically engineered organism should 
no longer be a regulated article because it doesn’t pose any plant-pest risk. Also, the US 
public was given the opportunity to be involved in these reviews, which is unusual. 
The dossier of information submitted to the agency supporting the contention that the 
genetically engineered organism is not a plant pest is available for public review—and 
comment—before final APHIS determination. 
These petitions involve two evaluations by APHIS. We make a risk assessment—as a 
stipulation of the Plant Protection Act—to answer the question: Does the genetically en-
gineered organism pose a plant-pest risk? And we make an environmental assessment—as a 
stipulation of the National Environmental Policy Act (NEPA, signed by Richard Nixon in 
970, setting standards for federal agencies to appraise the significance of environmental 
impacts that might arise from their decisions1). Under NEPA, the public again has the 
opportunity to provide input. This does not determine the agency’s decision, but it does 
inform the decision-making process.
To date, APHIS-BRS has made determinations of non-regulated status in response to 
over 90 petitions, comprising 6 plant species (Figure 6). Once non-regulated status is 
granted, the petitioner’s obligation under the regulation is finished: there is no license; 
there is no permit; nothing needs to be reviewed. Progeny derived from the organism 
through traditional plant breeding also has non-regulated status. For example, hundreds of 
varieties have been developed from the first glyphosate-tolerant soybean (“HT” in Figure 
6) to receive non-regulated status from us in the 990s. Likewise, hundreds of varieties 
1Back then, the decisions had nothing to do with genetically engineered organisms; they applied to federal 
agencies responsible for building bridges, dams, roads, etc.
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that have been developed from the early Bt corn genotypes (“IR” in Figure 6), with no 
obligation to apply for deregulation. Our statute is unrelated to commercialization; it 
strictly deals with safety issues. Some genetically engineered plants under regulation are 
actually being used as sources for commercial purposes, but all are being grown under 
permits.
Figure 6. Genetically engineered species with non-regulated
status under 7CFT part 340.
Commercialization is not under APHIS’s authority. Whether a product is commercial-
ized is market-driven. The left column in Figure 6 shows products that are on the market 
as of June 03, including the high-profile cases of herbicide-tolerant alfalfa and sugar 
beet, and less well known tobacco with reduced nicotine. Dennis Gonsalves’s2 papaya 
is also in the left column, And we have everything from insect resistance (“IR”) and 
drought tolerance (“AP”) in corn, through herbicide tolerance in canola (“HT”) to high 
oleic acid content in soybean (“PQ”). The right column includes the FlavrSavr ® tomato 
and another slow-ripening high-solids tomato. Male-sterile chicory (“AP”), sometimes 
called radicchio—developed in Belgium in the mid-990s—has non-regulated status, but 
does not have consumer approval in Europe. Several herbicide-tolerant rice lines have 
been through the system, but commercialization is pending, subject to approvals in other 
countries. The blue rose (“PQ”) and Ralph Scorza’s plum3 (“VR”) are also in the column 
on the right; they are gearing up for commercial release of the virus-resistant plum. Some 
others are on track for commercialization . 
2Pages 37–46.
3Page 36.
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Recent APHIS-BRS Initiatives
In 007, we initiated a voluntary compliance-assistance program, with early input from 
large companies, medium-size companies and public research institutions. An extensive 
effort in recent years has examined the petition process to make it more efficient. Over 
the years, we went from a six-month timeframe for completing reviews, to where it was 
taking up to several years. Petition-process improvement was put into place in 0. 
And in 008 we proposed amending the regulation. In the United States, a regulation 
is proposed and followed by a public-comment period, after which the regulation may 
be finalized. In this case, after announcement of the initial proposal, 66,000 comments 
were received and are still being appraised.
Figure 7. Guiding principles for regulating new technologies.
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Figure 8. For more information.
Future
In 0, a memorandum was issued by the White House Office of Science and Technol-
ogy Policy in conjunction with the Office of Management and Budget and the US Trade 
Representative’s Office—frequently referred to as the Holdren memo—titled Principles for 
Regulation and Oversight of Emerging Technologies. Although it is not aimed at biotechnol-
ogy alone, it is similar in tone and emphasis to the Coordinated Framework for Regulation 
of Biotechnology, i.e. favoring innovation, having enough regulation as necessary and to 
also consider that there may be no need for regulation.
Figure 7 shows key principles espoused in the Holdren memo. International coopera-
tion is becoming increasingly important, especially in the biotechnology area. Again, the 
benefits of a regulation should justify the costs it incurs. Are regulations the best approach? 
How much leeway is in the system? Technically, if you set up a class of things that are 
regulated, can you distinguish them from counterparts that are not regulated? Safety, of 
course, comes into play as part of public policy. The Holdren memo is an example of 
public policy that sets out international obligations. 
The Sanitary and Phytosanitary Agreement under the WTO, which came into being 
in 995 says, in essence: “In the absence of good scientific evidence that demonstrates 
harm to plants, animals or to humans, we should not restrict trade.” This lens may be 
applied to the regulatory systems in the United States and elsewhere.
The Secretary of Agriculture’s Advisory Committee on Biotechnology and Agriculture 
has, over the past two years, taken up the issue of coexistence. Although this has to do with 
crops after they’re out from under our regulatory system, APHIS-BRS has been involved 
in helping to bring stakeholders together for on-going discussions.
Figure 8 provides our website and means to obtain stakeholder-information updates 
via email.
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